Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Epizyme
Pharma
Safety signals prompt Ipsen to withdraw cancer med Tazverik
The move may not hamper Ipsen’s financials, but it could shake confidence in the company’s business development acumen, Jefferies analysts suggested.
Fraiser Kansteiner
Mar 9, 2026 10:07am
Dire straits detailed for Epizyme before buyout by Ipsen
Jul 13, 2022 8:46am
Ipsen snaps up Epizyme and cancer drug Tazverik for $247M
Jun 27, 2022 10:20am
Epizyme follicular lymphoma campaign showcases interactive coach
Nov 18, 2021 10:47am
COVID isn't solely to blame for Epizyme's slow cancer med launch
Feb 26, 2021 10:35am
Can Epizyme's Tazverik launch top Gilead's Zydelig?
Feb 25, 2020 11:17am
